AR020092A1 - Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, metodo para obtener anticuerpos contra el polipeptido - Google Patents
Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, metodo para obtener anticuerpos contra el polipeptidoInfo
- Publication number
- AR020092A1 AR020092A1 ARP990102961A AR020092A1 AR 020092 A1 AR020092 A1 AR 020092A1 AR P990102961 A ARP990102961 A AR P990102961A AR 020092 A1 AR020092 A1 AR 020092A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- virus
- strain
- nucleic acid
- isolated
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 12
- 238000000034 method Methods 0.000 title abstract 11
- 229920001184 polypeptide Polymers 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 10
- 241000700605 Viruses Species 0.000 title abstract 8
- 108020004707 nucleic acids Proteins 0.000 title abstract 7
- 102000039446 nucleic acids Human genes 0.000 title abstract 7
- 150000007523 nucleic acids Chemical class 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 6
- 208000006454 hepatitis Diseases 0.000 title abstract 2
- 231100000283 hepatitis Toxicity 0.000 title abstract 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 title 1
- 238000004690 coupled electron pair approximation Methods 0.000 title 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 2
- 238000002955 isolation Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 229960002520 hepatitis vaccine Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
Abstract
Cepa aislada de virus de hepatitis B designada antíngeno de superificie de virus de hepatitis B humana-cepaS145 Singapur (glicina a arginina) cuyo genomaviral constituyente está depositado bajo los numeros de acceso P97121504, P97121505 y P97121506 en la Coleccion Europea de Cultivos de Células del 15 deDiciembre de 1997. Un ácido nucleico aislado que codifica un polipéptido que es un antígeno mayor mutante de superficie del virus, un vector que comprendedicho ácido nucleico, un sistema vector huesped para la produccion de polipéptido de la cepa aislada de virus, un método para producir dicho polipéptido, unmétodo para producir un péptido, un polipéptido de dicha cepa aislada de virus, un oligonucleotido que hibridiza con el ácido nucléico,método para obteneranticuerpos para el polipéptido, un anticuerpo obtenido por el método, un método para determinar la infeccion en un sujeto, un método para identificar uncompuesto químico, una composicion que comprende un péptido, un método para tratar un sujeto infectado, un método para evitar una infeccion, un método pararastrear fluidos en el sujeto, una vacuna contra hepatitis que comprende la cepa del virus de hepatitis. Esta invencion provee una cepa aislada de virus dehepatitis B designada antígeno de superficie de virus de hepatitis B humana-cepaS133 Oon (metionina o trionina) cuyo genoma viral constituyente está depositadobajo los numeros de acceso P971221501,P97121502 y P97121503 en la Coleccion Europea de Cultivos de Células del 15 de Diciembre de 1997. Esta invencion proveetambién ácido nucleico aislado que codifica un polipéptido que es un antígeno mayor mutante de superficie de una cepa de virus de hepatitis B. La aislacion delvirus mutante permite el secuenciado de los ácidos nucleicos y los polipéptidos de los virus, los cuales a cambio permiten la produccion de varios métodos loscuales no son posibles previo a la aislacion del virus. Estos métodos incluyen, pero no son limitantes a los métodos de deteccion de infeccion, métodos detratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG1998/000045 WO1999066047A1 (en) | 1998-06-19 | 1998-06-19 | A vaccine-induced hepatitis b viral strain and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020092A1 true AR020092A1 (es) | 2002-04-10 |
Family
ID=20429861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102961 AR020092A1 (es) | 1998-06-19 | 1999-06-18 | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, metodo para obtener anticuerpos contra el polipeptido |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7038035B1 (es) |
| EP (1) | EP1086232A1 (es) |
| JP (1) | JP2002518013A (es) |
| KR (1) | KR100498117B1 (es) |
| CN (1) | CN1255540C (es) |
| AR (1) | AR020092A1 (es) |
| AU (1) | AU756858B2 (es) |
| BG (1) | BG105065A (es) |
| BR (1) | BR9815912A (es) |
| CA (1) | CA2332173A1 (es) |
| HU (1) | HUP0103258A3 (es) |
| IL (1) | IL140363A0 (es) |
| IS (1) | IS5777A (es) |
| MX (1) | MXPA00012724A (es) |
| MY (1) | MY135991A (es) |
| NO (1) | NO20006457L (es) |
| NZ (1) | NZ508892A (es) |
| PL (1) | PL191312B1 (es) |
| TR (1) | TR200003778T2 (es) |
| UA (1) | UA73475C2 (es) |
| WO (1) | WO1999066047A1 (es) |
| YU (1) | YU80500A (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP967999A0 (en) | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
| AUPQ810900A0 (en) | 2000-06-09 | 2000-07-06 | Austin and Repatriation Medical Centre, The | Viral variants and methods of using same |
| CN100355777C (zh) * | 2003-02-10 | 2007-12-19 | 文洪模 | 乙型肝炎病毒pre－S突变蛋白及其制备方法与应用 |
| US20060057670A1 (en) * | 2004-09-10 | 2006-03-16 | The Chinese University Of Hong Kong | Genomic markers of hepatitis B virus associated with hepatocellular carcinomas |
| EP1806363B1 (en) * | 2004-09-22 | 2013-09-04 | Advanced Life Science Institute, Inc. | METHOD OF DETECTING HEPATITIS B VIRUS s ANTIGEN |
| WO2006132598A1 (en) * | 2005-06-07 | 2006-12-14 | Temasek Life Sciences Laboratory Limited | Porcine circovirus type 2 vaccines |
| CN101948932B (zh) * | 2010-07-22 | 2013-04-03 | 中国人民解放军第三〇二医院 | 滚环扩增加跨缺口荧光定量PCR检测乙型肝炎病毒cccDNA试剂盒 |
| CN101948933B (zh) * | 2010-07-22 | 2013-04-03 | 中国人民解放军第三〇二医院 | 检测石蜡包埋肝组织乙型肝炎病毒cccDNA的试剂盒 |
| RU2586513C1 (ru) * | 2015-04-24 | 2016-06-10 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ МУТАНТНОГО ПОВЕРХНОСТНОГО АНТИГЕНА ВИРУСА ГЕПАТИТА В (ВАРИАНТЫ) |
| RU2603729C2 (ru) * | 2015-04-24 | 2016-11-27 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты) |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| CN113201051B (zh) * | 2021-04-27 | 2022-08-02 | 复旦大学 | 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9007024D0 (en) * | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
| US5955089A (en) * | 1993-04-20 | 1999-09-21 | Uab Research Foundation | Strain selection of pneumococcal surface proteins |
| GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
| US5830759A (en) * | 1994-08-18 | 1998-11-03 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| US5980901A (en) | 1996-09-18 | 1999-11-09 | The Board Of Regents Of The University Of Texas System | Viral defective interfering particles and uses thereof |
-
1998
- 1998-06-19 HU HU0103258A patent/HUP0103258A3/hu not_active Application Discontinuation
- 1998-06-19 NZ NZ50889298A patent/NZ508892A/xx unknown
- 1998-06-19 US US09/719,533 patent/US7038035B1/en not_active Expired - Fee Related
- 1998-06-19 UA UA2000127296A patent/UA73475C2/uk unknown
- 1998-06-19 AU AU77950/98A patent/AU756858B2/en not_active Ceased
- 1998-06-19 KR KR10-2000-7014443A patent/KR100498117B1/ko not_active Expired - Fee Related
- 1998-06-19 MX MXPA00012724A patent/MXPA00012724A/es unknown
- 1998-06-19 IL IL14036398A patent/IL140363A0/xx unknown
- 1998-06-19 TR TR200003778T patent/TR200003778T2/xx unknown
- 1998-06-19 CA CA002332173A patent/CA2332173A1/en not_active Abandoned
- 1998-06-19 YU YU80500A patent/YU80500A/sh unknown
- 1998-06-19 WO PCT/SG1998/000045 patent/WO1999066047A1/en not_active Ceased
- 1998-06-19 EP EP19980926022 patent/EP1086232A1/en not_active Withdrawn
- 1998-06-19 CN CNB988142007A patent/CN1255540C/zh not_active Expired - Fee Related
- 1998-06-19 BR BR9815912A patent/BR9815912A/pt not_active Application Discontinuation
- 1998-06-19 JP JP2000554856A patent/JP2002518013A/ja active Pending
- 1998-06-19 PL PL345203A patent/PL191312B1/pl not_active IP Right Cessation
-
1999
- 1999-06-17 MY MYPI99002505A patent/MY135991A/en unknown
- 1999-06-18 AR ARP990102961 patent/AR020092A1/es unknown
-
2000
- 2000-12-18 NO NO20006457A patent/NO20006457L/no not_active Application Discontinuation
- 2000-12-18 BG BG105065A patent/BG105065A/xx unknown
- 2000-12-19 IS IS5777A patent/IS5777A/is unknown
-
2006
- 2006-03-20 US US11/385,013 patent/US20070026422A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20006457D0 (no) | 2000-12-18 |
| MXPA00012724A (es) | 2003-02-10 |
| UA73475C2 (en) | 2005-08-15 |
| WO1999066047A1 (en) | 1999-12-23 |
| YU80500A (sh) | 2004-05-12 |
| IS5777A (is) | 2000-12-19 |
| EP1086232A1 (en) | 2001-03-28 |
| AU7795098A (en) | 2000-01-05 |
| NO20006457L (no) | 2001-02-16 |
| KR100498117B1 (ko) | 2005-07-01 |
| IL140363A0 (en) | 2002-02-10 |
| HUP0103258A2 (hu) | 2001-12-28 |
| PL191312B1 (pl) | 2006-04-28 |
| CA2332173A1 (en) | 1999-12-23 |
| BR9815912A (pt) | 2002-02-05 |
| TR200003778T2 (tr) | 2001-06-21 |
| HUP0103258A3 (en) | 2003-10-28 |
| US7038035B1 (en) | 2006-05-02 |
| BG105065A (en) | 2001-09-28 |
| NZ508892A (en) | 2004-02-27 |
| CN1304453A (zh) | 2001-07-18 |
| AU756858B2 (en) | 2003-01-23 |
| PL345203A1 (en) | 2001-12-03 |
| US20070026422A1 (en) | 2007-02-01 |
| JP2002518013A (ja) | 2002-06-25 |
| CN1255540C (zh) | 2006-05-10 |
| KR20010106128A (ko) | 2001-11-29 |
| MY135991A (en) | 2008-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1265648A (en) | Leukemia-associated virus immunogen, vaccine and assay | |
| CN111603557A (zh) | 一种包膜替换型病毒载体疫苗及其构建方法 | |
| JP4444372B2 (ja) | 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント | |
| CN107921115B (zh) | 新颖杆状病毒载体及使用方法 | |
| JP2007502612A (ja) | コロナウイルス、核酸、蛋白質、ならびにワクチンの生成方法、薬剤および診断 | |
| AR020092A1 (es) | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, metodo para obtener anticuerpos contra el polipeptido | |
| JP2008505050A (ja) | Ｓａｒｓコロナウイルスｓタンパク質およびその使用 | |
| CA2427578A1 (en) | A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine | |
| Camacho et al. | Protein p22 of African swine fever virus: an early structural protein that is incorporated into the membrane of infected cells | |
| WO2006009011A1 (ja) | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター | |
| Emini et al. | Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine | |
| HUP9901005A2 (hu) | Herpeszvírusok RFHV/KSHV-alcsaládjába tartozó vírusokból származó glikoprotein-B | |
| Wada et al. | Cytomegalovirus glycoprotein B sequence variation among Japanese bone marrow transplant recipients | |
| AR020093A1 (es) | Una cepa aislada de virus de hepatitis, acido nucleico aislado que codifica un polipeptido de la cepa, vector que comprende dicho acido nucleico, sistemavector huesped para la produccion del polipeptido, el polipeptido, metodo para su produccion, oligonucleotido para hibridarse con el acido nucleico | |
| KR20070050993A (ko) | Ｃ형 간염 바이러스 유래 펩티드 | |
| CA2338886A1 (en) | Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response | |
| CN115666633A (zh) | CpG-佐剂的SARS-CoV-2病毒疫苗 | |
| Xu et al. | Assessment of antigenicity and genetic variation of glycoprotein B of murine cytomegalovirus | |
| CN114213509B (zh) | 基于SARS-CoV-2的S蛋白的疫苗及其用途 | |
| US6777247B2 (en) | Nervous necrosis virus protein | |
| WO2000004921A1 (en) | Avian leukosis virus subgroup j envelope gene product for diagnosis and vaccine | |
| CN112262153A (zh) | 高效的肝炎病毒的抗体诱导方法、抗体以及检测系统 | |
| CN100479858C (zh) | 一种重组痘苗-sars疫苗及其制备方法 | |
| KR100785397B1 (ko) | 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신 | |
| CN114315984A (zh) | 一种用于制备prrsv基因ii型表位缺失疫苗毒株的n蛋白表位突变标记及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |